Voyager DSLT (direct selective laser trabeculoplasty) is a quick, in-office laser treatment that lowers eye pressure in glaucoma patients without relying on daily eye drops. Cleared by the FDA and now offered through Alcon’s Voyager platform, it treats the eye’s drainage tissue in seconds. For patients who struggle with drop adherence, it’s worth a conversation with a glaucoma specialist.
Nearly half of the 4.22 million Americans living with glaucoma do not know they have it, and among those already being treated, fewer than one in four keep up a daily eye drop regimen for a full year, according to research on glaucoma medication adherence. That gap between diagnosis and consistent treatment is precisely why Voyager DSLT (direct selective laser trabeculoplasty) has become one of the more talked-about developments in glaucoma care: a laser treatment that lowers eye pressure in seconds, without asking anyone to remember a bottle every morning and night. Anaheim Eye Institute has watched glaucoma treatment evolve since 1958, when it opened as Orange County’s first multi-specialty ophthalmology practice, and Voyager DSLT reflects one of the more meaningful shifts in that history: away from relying on memory, toward a single in-office procedure that keeps working long after the visit ends.
Why Glaucoma Treatment Is a Long Game
Glaucoma is a chronic, lifelong condition, not something a single visit resolves. It develops when pressure inside the eye, known as intraocular pressure, slowly damages the optic nerve that carries visual information to the brain. Because this damage is usually painless and produces no early symptoms, glaucoma is often called the silent thief of sight, and the Glaucoma Research Foundation estimates that vision loss from open-angle glaucoma, the most common form, tends to start at the edges of a person’s field of view, where it goes unnoticed the longest.
That is why treatment is measured in years, not weeks. The National Eye Institute says that intraocular pressure is the most important risk factor for glaucoma that can be changed, and its landmark Ocular Hypertension Treatment Study found that consistently lowering eye pressure cut the five-year risk of developing glaucoma roughly in half. The catch is that the word “consistently” carries a lot of weight in that sentence. Ongoing pressure control, not a onetime fix, protects vision over a lifetime, which is why our glaucoma team treats it as a long-term partnership rather than a single prescription.
When Daily Eye Drops Become the Hard Part
For decades, the standard first step in glaucoma treatment has been a daily prescription eye drop that lowers eye pressure. Drops work well when they are used correctly and consistently, but real-world adherence tells a more complicated story: most patients miss doses, and a large share stop the regimen entirely within months of starting it.
The numbers back this up. Poor adherence, defined as taking less than 75 percent of prescribed doses, shows up in roughly half of glaucoma patients, and a review of adherence barriers found that fewer than 25 percent of patients continue their drops for a full year without interruption. In surveys of ophthalmology practices, 62 percent of glaucoma patients reported trouble following their prescribed therapy, with the physical act of getting a drop into the eye cited most often, followed by cost and side effects like stinging or redness. None of this reflects a lack of effort. Aging hands, a busy week, travel, and the simple mechanics of tilting your head back and hitting a moving target all get in the way, which is exactly the kind of friction that has pushed glaucoma specialists to look harder at laser-based alternatives.
How Voyager DSLT Works
Voyager DSLT stands for direct selective laser trabeculoplasty, a treatment that uses a low-energy laser to improve drainage inside the eye rather than trying to manage pressure with medication every day. The “trabeculoplasty” part refers to the trabecular meshwork, a mesh-like drainage tissue inside the eye that controls how fluid exits and, in turn, how much pressure builds up.
Traditional selective laser trabeculoplasty already had a strong track record, but it required a handheld contact lens placed directly on the numbed eye so the doctor could aim the laser point by point. Voyager DSLT, originally developed by Belkin Vision and now part of Alcon’s ophthalmology portfolio after a 2024 acquisition, removes that step. According to coverage of the platform’s 2025 US launch, an automated imaging system locates the treatment area and delivers laser energy around the full 360 degrees of the drainage angle in about 2.3 seconds, without a contact lens or numbing drops touching the eye at all. The result is a treatment that takes only a few minutes in the chair and stimulates the eye’s own drainage system to work more efficiently going forward.
Voyager DSLT vs. Traditional SLT and Daily Drops
Selective laser trabeculoplasty, in either its traditional or direct form, is no longer considered a backup plan. The American Academy of Ophthalmology and the European Glaucoma Society both recognize SLT as an appropriate initial treatment for open-angle glaucoma and ocular hypertension, on equal footing with eye drops rather than as a last resort.
The evidence behind that shift is substantial. The UK-based LiGHT trial, published in the American Academy of Ophthalmology’s journal, followed patients for six years and found that more than 70 percent of eyes treated with laser first maintained healthy pressure without any medication or surgery while also showing slower disease progression and less need for later glaucoma or cataract procedures. A separate clinical review noted that 74.2 percent of SLT patients remained completely drop-free three years after treatment. Voyager DSLT builds on that same mechanism; what changes is convenience, since removing the contact lens and manual aiming step lets the procedure finish faster and with less discomfort.
Who Is a Good Candidate for Voyager DSLT
Voyager DSLT tends to work best for people with open-angle glaucoma or ocular hypertension, the two conditions it has been most thoroughly studied in. On average, SLT-based treatments lower eye pressure by 20 to 30 percent, and the Glaucoma Research Foundation notes that the laser succeeds in roughly 80 percent of appropriately selected patients. It is not, however, a fit for every form of glaucoma, and a short conversation with a specialist is the only reliable way to know where a given patient falls.
- Typically a reasonable candidate: someone newly diagnosed with open-angle glaucoma or ocular hypertension, someone whose pressure is only partially controlled on drops, or someone who has struggled with drop adherence due to cost, technique, or side effects.
- Typically not a first choice: someone with narrow-angle or angle-closure glaucoma, significant scarring or prior damage to the eye’s drainage angle, active eye inflammation, or certain rare secondary forms of glaucoma where the underlying cause needs to be addressed directly.
Voyager DSLT does not replace the need for eye care, it replaces the daily burden of remembering a bottle.
What to Expect During and After Treatment
Voyager DSLT is an in-office procedure with no incisions, no needles, and typically no numbing drops, so most patients are back to normal activities the same day. Because the laser is applied without a contact lens, the visit itself is brief, often just a few minutes for the actual treatment plus routine pressure checks before and after.
Mild, short-lived side effects are common and expected rather than concerning. Some patients notice light sensitivity, mild redness, or a gritty feeling for a few hours afterward, and in rare cases a temporary pressure spike or inflammation can occur, which is why a follow-up assessment is standard practice. The pressure-lowering effect builds gradually over the following weeks rather than appearing instantly, and because SLT-based treatments are repeatable, a second session remains an option later if needed. Some patients still use a reduced number of drops afterward, particularly with more advanced glaucoma, and because well-controlled eye pressure is linked to a reduced need for later glaucoma or cataract surgery, addressing pressure early can simplify a patient’s eye care for years to come.
Talking to Your Doctor About Glaucoma Treatment Options
The right glaucoma treatment plan depends on the type and stage of glaucoma, overall eye health, and how a person has responded to any prior therapy, which makes an honest conversation with a fellowship-trained specialist the most important next step. Because glaucoma rarely announces itself with symptoms, regular comprehensive eye exams matter just as much as the treatment itself, and those same visits often catch other silent conditions early, including changes in the retina that a patient would otherwise never notice on their own.
Anyone currently managing glaucoma with drops, especially if the routine feels like a daily struggle, has good reason to ask whether Voyager DSLT or another laser option fits their situation. Anyone with a family history of glaucoma or elevated eye pressure found during a routine exam has equally good reason to ask about it before daily drops become necessary at all.
The Bottom Line on Voyager DSLT
Glaucoma will always require ongoing attention, but the tools for managing it keep getting less burdensome. Voyager DSLT offers a genuine, evidence-backed way to lower eye pressure without leaning on a daily drop routine that, for many patients, was never sustainable to begin with. It is not a cure and will not eliminate the need for regular eye exams, but for the right candidate, it can meaningfully lighten the day-to-day load of managing glaucoma.
Have questions about your vision or ready to explore your options? The team at Anaheim Eye Institute has been helping Orange County patients see clearly since 1958. Book an Appointment or call 714.533.2020.
This article is for general educational purposes only and is not a substitute for a personal evaluation, diagnosis, or treatment recommendation from a qualified eye care professional. Whether Voyager DSLT or any other glaucoma treatment is appropriate for you depends on your individual eye health and should be discussed directly with your doctor.
FAQ
What is Voyager DSLT and how is it different from regular SLT? Voyager DSLT is a direct selective laser trabeculoplasty device that lowers eye pressure by treating the eye’s natural drainage tissue. Unlike traditional selective laser trabeculoplasty, it does not require a handheld contact lens on the eye; an automated imaging system aims the laser instead, which typically makes the visit faster and more comfortable.
Does Voyager DSLT hurt, and what does recovery look like? Most patients describe the treatment as quick and only mildly uncomfortable, if noticeable at all, since no incisions or numbing drops are typically needed. Mild light sensitivity, redness, or grittiness can occur for a few hours afterward, and most people resume normal activities the same day.
Will Voyager DSLT completely replace my need for eye drops? For many patients, particularly those with earlier-stage glaucoma, it can reduce or eliminate the need for daily drops. Patients with more advanced glaucoma may still need some medication alongside the laser treatment, so results vary and should be discussed with your doctor.
How long does the pressure-lowering effect from Voyager DSLT last? Effects build gradually over the weeks following treatment and can last for a year or more in many patients, though individual results vary based on glaucoma type and severity. Because SLT-based treatments are repeatable, a follow-up session can be performed later if eye pressure rises again.
Is Voyager DSLT covered by insurance? Selective laser trabeculoplasty procedures, including DSLT, are generally covered by Medicare and most major insurance plans when medically indicated for glaucoma or ocular hypertension. Coverage details vary by plan, so it is best to confirm specifics with your insurance provider and our office before scheduling.
